Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

This study is evaluating the safety of giving a second dose of a CAR-T cell therapy (called axi-cel) to patients with aggressive B-cell lymphoma who relapsed after receiving their first axi-cel treatment as standard of care. **You may be eligible if...** - You have been diagnosed with a specific type of aggressive B-cell non-Hodgkin lymphoma (such as DLBCL or related types) - You received axi-cel as your second-line treatment (standard of care) and your cancer came back or did not respond - Your cancer is considered high-risk based on specific lab values (LDH above normal range) - You meet additional organ function and health criteria **You may NOT be eligible if...** - Your lymphoma is not one of the listed subtypes - You do not meet health or organ-function requirements your doctor will review Talk to your doctor to see if this trial is right for you.